Philip Grant: Clinical Trials

2 trials sponsored by Philip Grant, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 withdrawn. 2 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Withdrawn 1
Phase 31Completed 1

Follow Philip Grant: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)
Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC), Current tenofovir alafenamide (TAF)-containing ART regimen - HIV/AIDS, HIV-1-infection
Phase 2WithdrawnPhilip Grant2019-08-012021-03-15
Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir
Rilpivirine/Emtricitabine/Tenofovir - HIV
Phase 2 / Phase 3CompletedPhilip Grant1502014-04-012021-03-17

Conditions studied

Acquired Immunodeficiency Syndrome (1)  ·  Bone Diseases, Metabolic (1)

Interventions

Emtricitabine, Rilpivirine, Tenofovir Drug Combination (1)  ·  Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination (1)  ·  Lamivudine (1)  ·  Rilpivirine (1)  ·  dolutegravir (1)

Countries

Rwanda (1)  ·  United States (1)

Top investigators

Andrew Zolopa, MD (1)